Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Change in the disclosure date of Delete’s January-September 2019 interim review

Delete Group Oyj | Stock Exchange Release, 5 November 2019 at 12:00 AM/PM (EEST) NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO ANY JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. Unlike previously announced, Delete will disclose the January–September 2019 interim review already on 12 November 2019. The earlier announced disclosure date for the January–September 2019 interim review was 15 November 2019. Delete Group Oyj FOR FURTHER INFORMATION, PLEASE CONTACT: Delete Group Oyj Ville

SBB announces final tender results for outstanding SEK perpetual capital securities

NOT FOR DISTRIBUTION IN OR INTO OR TO ANY PERSON LOCATED OR RESIDENT IN THE UNITED STATES, ITS TERRITORIES AND POSSESSIONS (INCLUDING PUERTO RICO, THE U.S. VIRGIN ISLANDS, GUAM, AMERICAN SAMOA, WAKE ISLAND AND THE NORTHERN MARIANA ISLANDS, ANY STATE OF THE UNITED STATES AND THE DISTRICT OF COLUMBIA) OR TO ANY U.S. PERSON (AS DEFINED IN REGULATION S OF THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED) OR IN ANY JURISDICTION WHERE IT IS UNLAWFUL TO RELEASE, PUBLISH OR DISTRIBUTE THIS DOCUMENT. THE DISTRIBUTION OF THIS DOCUMENT IN CERTAIN JURISDICTIONS (IN PARTICULAR, THE UNITED STATES AND

Statement by the Board of Directors of Karessa Pharma in relation to the Merger with Klaria Pharma

The Board of Directors of Karessa Pharma unanimously recommends that the shareholders of Karessa Pharma vote in favour of the Merger. [1]Background This statement is made by the Board of Directors (the "Board") of Karessa Pharma Holding AB (publ) ("Karessa") pursuant to Section II.19 of the Swedish Corporate Governance Board’s Takeover Rules for certain trading platforms (the "Takeover Rules"). Today, on 5 November 2019, Klaria Pharma Holding AB (publ) ("Klaria") and Karessa jointly announced that the board of Klaria and the board of Karessa have agreed on a statutory merger between

DreamHack Winter to host European Smash Ball Team Cup Nordic Finals

Teams from Denmark, Finland, Norway, and Sweden to battle out for a spot in the European finalsSTOCKHOLM – DreamHack, the premier gaming lifestyle festival, in partnership with Nintendo has announced that the 2019 edition of DreamHack Winter , November 29 - December 1, will host the Nordic finals of the European Smash Ball Team Cup. European Smash Ball Team Cup is Nintendo’s way to gather the top Super Smash Bros. Ultimate in Europe in order to crown the very best. All Nintendo Switch players interested in participating can form a team of three players to

Orion continues to rely on Caverion’s services: Caverion is responsible for Technical Maintenance and Managed Services for Orion’s properties

Caverion Corporation Investor news 5 November 2019 at 10.30 a.m. EETOrion continues to rely on Caverion’s services: Caverion is responsible for Technical Maintenance and Managed Services for Orion’s properties Caverion is responsible for the Technical Maintenance of and Managed Services for Orion’s properties in four locations in Finland (Espoo, Turku, Salo and Kuopio). The companies have agreed to continue the cooperation started in 2009 for an indefinite period. The total floor area of the properties covered by the agreement is approximately 195,000 square metres. The value of the

Minutes of the Monetary Policy Meeting held on 23 October 2019

At the Monetary Policy Meeting on 23 October 2019, the Executive Board of the Riksbank decided to leave the repo rate unchanged at –0.25 per cent. As in September, the forecast for the repo rate indicates that the rate will most probably be raised in December to zero per cent. However, low interest rates abroad and continued uncertainty over global and Swedish economic activity mean that the forecast for the repo rate has thereafter been revised downwards and indicates that the repo rate will be unchanged for a prolonged period after the expected rise in December.The board members supported

New large-scale Antarctic krill survey confirms healthy krill biomass

5 November 2019      New international research surveying the krill biomass around the Antarctic Peninsula finds more krill than was found in the last large-scale krill survey conducted in year 2000. The findings and analysis at the Commission for the Conservation of Antarctic Marine Living Resources (CCAMLR) annual meeting confirms 62,6 million tonnes of krill in Area 48 off the Antarctic peninsula. This survey carried out by the Institute of Marine Research is the first large-scale scientific investigation of the krill population in the Southern Ocean fishery in 19 years. In 2000,

For the first time in UK, a wider audience can get first-hand experience of the NeoNavia® micropulse biopsy system for breast cancer

During the annual meeting of the British Society of Breast Radiology (BSBR) on 3-5th November in Bristol, radiologists get to gain first-hand experience using the innovative micropulse technology in meat models via a series of hands-on workshops arranged by NeoDynamicsHigh interest in the workshops has led to additional sessions being added and over 50 radiologists being able to try the new system. The BSBR workshops represent a milestone for NeoDynamics and for the first time a wider audience will get to not only hear about the NeoNavia system but try it for themselves. "With the UK

Nomination committee appointed ahead of 2020 Annual General Meeting of Pricer AB

Pricer AB (publ) has appointed the nomination committee ahead of the 2020 Annual General Meeting. In accordance with the decision at the Annual General Meeting on April 25, 2019 Pricer’s Chairman of the Board Bernt Ingman has contacted the company’s largest shareholders to form a Nomination Committee. The Chairman has, when selecting the largest shareholders, given due consideration to groups of shareholders who have indicated a wish to participate jointly in the Nomination Committee. The shareholders and representatives comprising the Nomination Committee, in addition to the Chairman

Modern classics, retro sport and colour explosions in this spring’s Limited Edition

This March, KappAhl launches its much-anticipated new Limited Edition collection. Bold, timeless, and strongly influenced by retro sport styles, the collection embraces spring’s colours, creating an updated wardrobe with new silhouettes and details.-    “This spring’s Limited Edition will hit stores just as we are starting to dream of the perfect spring wardrobe. The collection is influenced by retro sport styles, combined with a more preppy look. We have challenged the classic base of the collection with new volumes and peppy colours, to create a wonderfully fresh spring look,” says

UPM closes paper machine 2 in Rauma – Employee consultation processes concluded

(UPM, Helsinki, 5 November 2019 at 10:00 EET) – In early September UPM announced plans to permanently close paper machine 2 in Rauma, Finland. The employee consultation processes have now been completed. Paper machine 2 in Rauma will be permanently closed on 6 November 2019. The reduction of personnel is 179 (159 permanent and 20 temporary contracts not prolonged). Following the closure, SC paper production capacity will be reduced by 265.000 tonnes annually. The production on the remaining two paper machines in Rauma will continue as before. “The recent weeks have not been easy for

Klaria Pharma Holding and Karessa Pharma Holding merge to create a focused drug development company with a strong pipeline and a wholly-owned drug-delivery technology platform

Important InformationIn the information below, “this press release” refers to this document, its content or part thereof, oral presentations, question papers and written or oral material discussed or distributed in connection therewith. This press release is not a notice to attend an extraordinary general meeting or a merger document. This press release is also not an offer to sell, or a solicitation or invitation to submit an offer to buy, acquire or subscribe for, securities, or an incentive to make any investment, and there will be no sale of securities in jurisdictions where such an

Klaria Pharma Holding and Karessa Pharma Holding merge to create a focused drug development company with a strong pipeline and a wholly-owned drug-delivery technology platform

Klaria Pharma Holding and Karessa Pharma Holding merge to create a focused drug development company with a strong pipeline and a wholly-owned drug-delivery technology platformKlaria Pharma Holding and Karessa Pharma Holding merge to create a focused drug development company with a strong pipeline and a wholly-owned drug-delivery technology platform

ASSMANN Büromöbel opens a showroom in Manchester

Having acquired segments of Frem Group Screens Ltd. last year, the German furniture manufacturer continues to build on its presence in the United KingdomWith successful showrooms already in operation in London and Glasgow, ASSMANN Büromöbel GmbH & Co. KG officially opened the doors to its new ASSMANN showroom in Manchester in mid-October. More than 100 visitors celebrated with the German mid-sized company, which is one of the UK's best-performing office furniture manufacturers. "With the new showroom in Manchester, we will have an even greater presence in the UK market!", managing partner

Midsona publishes prospectus relating to the rights issue

NOT FOR DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SWITZERLAND, THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR OTHER MEASURES BESIDES THOSE REQUIRED BY SWEDISH LAW. ADDITIONAL RESTRICTIONS APPLY. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THE PRESS RELEASE.The prospectus, relating to the rights issue in Midsona AB (publ) (“Midsona”) of approximately SEK 600 million after issue costs, has

Limited liability companies and co-operatives must submit financial statements to the Finnish Trade Register; even active businesses may risk deregistration

The Finnish Patent and Registration Office (PRH) will this week send reminder letters to about 5.000 limited liability companies and co-operatives that have not submitted their financial statements for registration within one year from the end of the financial period. The PRH can deregister even an active limited liability company or co-operative if they do not file the financial statements by the date given on the letter.Deregistration means that the business is out of action. All limited liability companies and co-operatives must file their financial statements with the Trade Register

Interim report January - September 2019

A quarter of recordsThird quarter July - September 2019 · Net sales amounted to 282.7 MSEK (232.2), which is an increase by 21.7 percent compared to the corresponding quarter last year. At comparable exchange rates and adjusted for acqusitions[1)] sales increased by 8.1 percent. · Operating profit increased by 42.5 percent to 64.3 MSEK (45.1). · Result after tax increased by 51.3 percent to 66.6 MSEK (44.0). · Earnings per share increased to 1.02 SEK (0.68) before and after dilution. · The cash flow from operating activities increased to 80.0 MSEK (50.7). · Net debt[1)]

Very strong increase of sales during the third quarter

Q3 · Net sales reached SEK 19.5 (13.2) million. · Result after tax came in at SEK -7.7 (-9.6) million. · Earnings per share, basic and diluted, were SEK-0.05 (-0.11). · Cash and cash equivalents were SEK 30.7 (9.5) million. Significant events in Q3 · Enzymatica launched ColdZyme® Strawberry and broadened use to include soothe sore throat and alleviate common cold symptoms. · Sales surged on the Swedish market and ColdZyme continued to capture market share in terms of both value and volume. Sales on the Danish and Spanish markets also showed strong growth. ·

Interim report January - September 2019

NET ASSET VALUE AND THE LATOUR SHARE · The net asset value rose to SEK 127 per share, compared with SEK 100 per share at the start of the year. This is an increase of 29.9 per cent, adjusted for dividends. By comparison, the Stockholm Stock Exchange's Total Return Index (SIXRX) increased by 23.0 per cent. The net asset value was SEK 133 per share at 4 November.(1) · The total return on the Latour share was 17.9 per cent during the period measured against the SIXRX, which rose 23.0 per cent. INDUSTRIAL OPERATIONS The third quarter · The industrial operations' order intake

Bioservo Technologies AB Interim report 1 January to 30 September 2019

Third quarter in figures · Net sales SEK 1.7 M (1.0) · EBITDA of SEK -4.6 M (-5.8) · EBIT of SEK -5.5 M (-6.7) · Earnings for the period was SEK -5.5 M (-6.7) · Earnings per share before and after dilution amounted to SEK -0.61 (-0.75) · At 30 September, cash and cash equivalents were SEK 9.4 M (32.1)   First nine months in figures · Net sales SEK 6.9 M (4.0) · EBITDA of SEK -13.8 M (-14.9) · EBIT of SEK -16.6 M (-17,2) · Earnings for the period was SEK -16.6 M (-17.2) · Earnings per share before and after dilution amounted to SEK -1.86 (-1.93) ·

Kallelse till extra bolagsstämma i TargetEveryOne AB (publ)

Aktieägarna i TargetEveryone AB (publ), org. nr. 556526-6748 (”Bolaget”), kallas härmed till extra bolagsstämma den 20 november 2019 klockan 11 på Kungsgatan 60, 1 tr. i Stockholm. Aktieägare som vill delta i stämman ska dels vara införda i den av Euroclear Sweden AB förda aktieboken den 14 november 2019, dels anmäla sitt deltagande till Bolaget senast den 14 november 2019, per post till adress TargetEveryOne AB, Kungsgatan 60, 1 tr, 112 22 Stockholm, eller per e-post (e-post_info@targeteveryone.com) info@targeteveryone.com. Vid anmälan anges namn, adress, telefonnummer, person- eller

Termination of project regarding ROR-gamma

In December 2011, Karo Pharma Aktiebolag (”Karo Pharma”) entered into a research collaboration and license agreement with Pfizer, with the purpose of discovering and developing substances that hamper the activity in the nuclear hormone receptor ROR-gamma, for treatment of autoimmune diseases. After completion of the initial research collaboration, Pfizer has conducted the development work in-house, in accordance with the terms of the agreement. Pfizer has informed Karo Pharma about its decision to terminate the specific development project, PF-06763809. As a result, Karo Pharma will not

Klaria acquires Uppsalagruppen and becomes the owner of the patent that protects Klaria’s technology platform

Klaria Pharma Holding AB (publ) (“Klaria”) today acquires Uppsalagruppen Medical AB (“Uppsalagruppen”) and the patent that protects Klaria’s drug delivery technology.  To date, Klaria has had a license from Uppsalagruppen to this patent for specific molecules.  With this acquisition, Klaria will now own the patent and have full freedom to develop novel drug candidates in the future.The transaction is structured as a share transfer agreement between the owners of Klaria and Uppsalagruppen, whereby all shares in Uppsalagruppen are acquired by Klaria. As consideration, Klaria has agreed to pay

Aspire Global’s Interim Report for the Third Quarter 2019 – Two Years of Sustained Growth

Third Quarter 2019 (JUL-SEP) · Revenues increased by 16.2% to €33.2 million (28.6) · B2B revenues increased by 37.9% to €21.0 million (15.2), constituting 63.0% of total revenues · EBITDA decreased by 16.0% to €5.2 million (6.2) · EBITDA for B2B increased by 15.0% to €4.3 million (3.7), constituting 82.0% of total EBITDA · EBITDA margin amounted to 15.7% (21.6%) · EBIT decreased to €4.3 million (5.7) · Earnings after tax decreased to €4.4 million (5.3) · Earnings per share after tax decreased to €0.09 (0.11) · First time depositors (FTDs) increased by 24.0% to

There are no items matching the current filter
There are no more items matching the current filter
Back to top